Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers
TORONTO and CAMBRIDGE, MA, June 5, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer's disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world's most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care. ProMIS' Chief Development Officer Dr. Johanne Kaplan will present the company's lead therapeutic candidate PMN310 which demonstrates high selectivity for the toxic forms of amyloid beta implicated as a root cause of Alzheimer's disease.
In the poster, "Selective targeting of HHQK conformational epitope in amyloid-beta oligomer species by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer's disease," Dr. Kaplan will present data for PMN310 that show:
- Superior selectivity for amyloid beta (AßOs) toxic oligomers.
- Potential to safely administer high doses of PMN310 with a reduced risk of brain swelling or ARIA.
- Potential to show greater therapeutic potency compared with other Aß-directed antibodies.
"Evidence continues to mount, showing that amyloid-beta toxic oligomers (AßO) - not amyloid plaque - are the key target for Alzheimer's disease therapy," said Dr. Johanne Kaplan. "The current therapeutic gap lies in how to effectively neutralize the toxic oligomer without wasting antibody on non-toxic forms of the protein. We're pleased our data will help inform discussions regarding future directions among the world's most accomplished researchers. Our data will demonstrate the unique ability of the ProMIS discovery platform to generate antibodies that bind the toxic species of amyloid beta while preserving healthy forms of the protein. Humanized PMN310 is currently in advanced preclinical development."
The conference, Keystone Symposia on Molecular and Cellular Biology, Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, takes place on June 16-20, 2019 at Keystone Resort in Keystone, Colorado. For more information, please visit www.keystonesymposia.org.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
For further information: For media inquiries, please contact: Shanti Skiffington, email@example.com, Tel. 617 921-0808; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, firstname.lastname@example.org, Tel. 617 901-0785